Cellect LLC v. Vidal: Supreme Court Denies Cert on ODP & Patent Term Adjustment
Cellect, LLC petitioned the U.S. Supreme Court to review whether obviousness-type double patenting can invalidate patents that received patent term adjustment under 35 U.S.C. § 154. The Court denied the petition after 140 days, leaving the Federal Circuit’s ruling intact and setting a significant precedent for patent portfolio holders who rely on PTA-extended terms.
Supreme Court closes the door on ODP challenge to PTA-extended patents
Cellect, LLC filed a petition for writ of certiorari with the U.S. Supreme Court on May 20, 2024, in case No. 23-1231, naming USPTO Director Katherine K. Vidal as respondent. The dispute arose from inter partes reexamination proceedings in which four Cellect patents — US7002621B2, US6982742B2, US6452626B1, and US6424369B1 — covering reduced-area imaging devices incorporated into communication and hand-held computing products were invalidated on grounds of obviousness-type double patenting (ODP). The central legal question was whether ODP applies to patents whose terms were extended by patent term adjustment granted to compensate for USPTO prosecution delays.
The Supreme Court denied the petition on October 7, 2024, 140 days after it was filed. A cert denial is not a merits ruling; the Court expressed no view on whether the Federal Circuit correctly resolved the ODP-PTA question. However, the practical effect is conclusive for Cellect: the Federal Circuit’s affirmance of the USPTO’s invalidity findings stands as binding precedent, and the four asserted patents remain unenforceable. Defendant Katherine K. Vidal, represented by Solicitor General Elizabeth Prelogar, successfully opposed certiorari.
The 140-day timeline is consistent with a straightforward cert denial at the conference stage, suggesting the Court did not find the ODP-PTA question sufficiently circuit-split or nationally significant to warrant plenary review — at least at this time. What the public record cannot confirm is whether the Solicitor General’s opposition brief was determinative, or whether the Court simply viewed the Federal Circuit’s ODP framework as settled. The question may resurface if another circuit or a differently-constituted Federal Circuit panel revisits PTA-ODP interaction.
Filing to Appeal Dismissed in 140 days
140 days from filing to denial — a typical cert petition lifecycle averages 90–150 days
Cert denied: what the Supreme Court’s refusal means for both parties
Cert denial ends the appeal without a merits ruling
A denial of certiorari means the Supreme Court declined to hear the case. It carries no precedential weight on the merits — the Court did not endorse or reject the Federal Circuit’s ODP-PTA reasoning. However, it leaves the Federal Circuit’s decision as the controlling law in U.S. patent practice, and no further appeal path exists for Cellect on these patents.
No merits adjudicationCellect’s four imaging patents remain invalidated
With cert denied, Cellect cannot enforce US7002621B2, US6982742B2, US6452626B1, or US6424369B1. Any licensing revenue or litigation leverage derived from those patents is extinguished. Importantly, the denial does not preclude Congress from amending the ODP-PTA framework legislatively, but Cellect itself has no remaining judicial remedy for this portfolio.
Patents unenforceableVidal and USPTO’s ODP-PTA position now stands unchallenged
The USPTO’s application of obviousness-type double patenting to PTA-extended patents survives the highest level of judicial review available. The agency’s approach — that a terminal disclaimer is required to overcome ODP even where term extension resulted from examiner delay — is now the settled rule unless Congress or a future en banc Federal Circuit reverses course.
Agency position upheldODP risk now priced into all PTA-extended patent portfolios
Patent owners across the imaging, semiconductor, and communications sectors who hold families with PTA-extended terms should reassess ODP exposure. The cert denial confirms that terminal disclaimers cannot be retroactively avoided by arguing PTA entitlement. Portfolio managers and licensing teams should audit for undisclaimed continuation chains before assertion, as the risk of invalidity via ODP is now firmly established.
Portfolio-wide ODP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cellect, LLC | Company | Patent holder in imaging device IP — holder of US7002621B2 and three related patentsSearch in Eureka ↗ |
| Defendant | Katherine K. Vidal | Individual | Katherine K. Vidal, Director of the USPTO, respondent in certiorari proceedingsSearch in Eureka ↗ |
| Plaintiff counsel | DANIEL N. LERMAN | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | James R. Hannah | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | JEFFREY C. THALHOFER | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | JEFFREY PRICE | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | JONATHAN CAPLAN | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lisa Kobialka | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | MATTHEW M. MADDEN | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Paul J. Andre | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Roy T. Englert | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Kramer Levin Naftalis & Frankel, LLP | Law Firm | Representing Cellect, LLCSearch in Eureka ↗ |
| Defendant counsel | Elizabeth B. Prelogar | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The one-word disposition — ‘Petition DENIED’ — is the standard form of a Supreme Court cert denial and carries no opinion or reasoning. It does not constitute a ruling on the merits of the ODP-PTA question Cellect raised. The Federal Circuit’s decision invalidating Cellect’s four patents on obviousness-type double patenting grounds therefore remains the operative, binding precedent for all U.S. patent practitioners. For the USPTO, the denial is a significant procedural win that insulates its reexamination practice from further challenge in this matter.
US7002621B2 and three related patents — imaging devices in communications and computing
The four patents at issue — US7002621B2, US6982742B2, US6452626B1, and US6424369B1 — all originate from application filings in the US09/9xxxxx series, suggesting a tightly linked continuation family filed around 2000–2001 during the early camera-phone era. They protect reduced-area imaging device architectures integrated into communication handsets and hand-held computers, a foundational technology category that underpinned the proliferation of mobile imaging before the smartphone generation.
Strategically, this family represents exactly the type of continuation portfolio that accumulated patent term adjustment due to extended USPTO prosecution — a common outcome for complex imaging and semiconductor claims filed in the early 2000s. The ODP invalidity ruling in these patents sends a clear signal to holders of comparable imaging, sensor, and communications continuation families: the PTA runway does not insulate a patent from double-patenting attack if a terminal disclaimer was not strategically deployed during prosecution. Competitors and licensees in the mobile imaging and consumer electronics sectors now face a lower bar when challenging these types of patents.
Should you run an FTO against US7002621B2 and the Cellect imaging patent family?
Product teams developing camera modules, image sensors, or compact imaging systems for integration into mobile communications devices, tablets, or hand-held computers should assess residual FTO risk from the broader Cellect family. While the four litigated patents have been invalidated, related family members or continuation-in-part applications may remain active and enforceable. The Cellect portfolio originated from a substantial continuation strategy — not all branches may have been subject to the same reexamination.
PatSnap Eureka’s FTO Search Agent can map the full Cellect continuation family, identify surviving claims, and flag any issued or pending patents with overlapping claim scope to your imaging or communications product. Eureka’s patent landscape tools also surface similar assignee portfolios that may pose parallel ODP-cleared risk in the reduced-area imaging space — giving R&D and legal teams a comprehensive clearance baseline before product launch.
Run a freedom-to-operate analysis on US7002621B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases: ODP, PTA, and USPTO reexamination in imaging and communications IP
Cases involving obviousness-type double patenting challenges to PTA-extended patents in the imaging and communications technology sector, including Federal Circuit and Supreme Court proceedings.
What Cellect v. Vidal signals for the patent portfolio IP landscape
The cert denial cements Federal Circuit ODP doctrine as governing law — with direct consequences for continuation-heavy patent portfolios.
Terminal disclaimer audits are now essential before any patent assertion
Cellect’s loss confirms that PTA-extended patents in continuation families are vulnerable to ODP invalidity if terminal disclaimers were not filed. Any portfolio holder asserting patents in communication or imaging technology should audit the full family for undisclaimed overlapping claims before filing suit or sending demand letters.
ODP exposure is a due diligence red flag in patent acquisitions
Acquirers of continuation-heavy U.S. patent portfolios — particularly in consumer electronics, imaging, and communications — should treat PTA-ODP exposure as a first-order diligence issue. The absence of terminal disclaimers in a family now represents a quantifiable invalidity risk that should be reflected in valuation and representations and warranties.
Cellect v Katherine — key questions answered
The Supreme Court denied Cellect’s petition for certiorari on October 7, 2024. The Court issued no opinion and made no ruling on the merits of the ODP-PTA question. The denial leaves intact the Federal Circuit’s decision invalidating Cellect’s four imaging patents on obviousness-type double patenting grounds.
The USPTO’s reexamination proceedings found that Cellect’s continuation patents, which had received patent term adjustment for examiner delays, were invalid under ODP because they claimed overlapping subject matter with earlier family members without terminal disclaimers filed to disclaim the extended term. The Federal Circuit affirmed, holding that PTA does not exempt a patent from ODP scrutiny.
A cert denial is not a merits ruling and carries no precedential value. However, it leaves the Federal Circuit’s ODP-PTA holding as the operative law governing U.S. patent practice on this issue. Until the Federal Circuit revisits the question en banc or Congress amends the relevant statutes, the Federal Circuit’s Cellect decision controls.
Four patents were at issue: US7002621B2, US6982742B2, US6452626B1, and US6424369B1. All relate to reduced-area imaging devices incorporated into communication handsets and hand-held computers, originating from a continuation family filed around 2000–2001. All four were found invalid in USPTO reexamination proceedings.
Patent holders with continuation families that received patent term adjustment should audit those portfolios for ODP exposure immediately. Where terminal disclaimers were not filed during prosecution of continuation applications, the risk of invalidity is now confirmed as real and judicially unreviewable at the Supreme Court level. New prosecution strategy should incorporate terminal disclaimers as a prophylactic measure where continuation chains overlap in subject matter.
PatSnap Eureka searches patents and litigation data to answer instantly.